Asset Details
Do you wish to reserve the book?
Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial
Do you wish to request the book?
Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial
2025
Overview
AbstractObjectiveTo assess the effect of dapagliflozin plus calorie restriction on remission of type 2 diabetes.DesignMulticentre, double blind, randomised, placebo controlled trial.Setting16 centres in mainland China from 12 June 2020 to 31 January 2023.Participants328 patients with type 2 diabetes aged 20-70 years, with body mass index >25 and diabetes duration of <6 years.InterventionsCalorie restriction with dapagliflozin 10 mg/day or placebo.Main outcome measuresPrimary outcome: incidence of diabetes remission (defined as glycated haemoglobin <6.5% and fasting plasma glucose <126 mg/dL in the absence of all antidiabetic drugs for at least 2 months); secondary outcomes: changes in body weight, waist circumference, body fat, blood pressure, glucose homoeostasis parameters, and serum lipids over 12 months.ResultsRemission of diabetes was achieved in 44% (73/165) of patients in the dapagliflozin group and 28% (46/163) of patients in the placebo group (risk ratio 1.56, 95% confidence interval (CI) 1.17 to 2.09; P=0.002) over 12 months, meeting the predefined primary endpoint. Changes in body weight (difference −1.3 (95% CI −1.9 to −0.7) kg) and homoeostasis model assessment of insulin resistance (difference −0.8, −1.1 to −0.4) were significantly greater in the dapagliflozin group than in the placebo group. Likewise, body fat, systolic blood pressure, and metabolic risk factors were significantly more improved in the dapagliflozin group than in the placebo group. In addition, no significant differences were seen between the two groups in the occurrence of adverse events.ConclusionThe regimen of dapagliflozin plus regular calorie restriction achieved a much higher rate of remission of diabetes compared with calorie restriction alone in overweight or obese patients with type 2 diabetes.Trial registrationClinicalTrials.gov NCT04004793.
Publisher
British Medical Journal Publishing Group,BMJ Publishing Group LTD
Subject
/ Aged
/ Benzhydryl Compounds - administration & dosage
/ Benzhydryl Compounds - therapeutic use
/ Body fat
/ Caloric Restriction - methods
/ Calories
/ China
/ Diabetes
/ Diabetes mellitus (non-insulin dependent)
/ Diabetes Mellitus, Type 2 - blood
/ Diabetes Mellitus, Type 2 - diet therapy
/ Diabetes Mellitus, Type 2 - drug therapy
/ Diabetes Mellitus, Type 2 - therapy
/ Energy
/ Exercise
/ Female
/ Glucose
/ Glucosides - administration & dosage
/ Glucosides - therapeutic use
/ Glycated Hemoglobin - analysis
/ Humans
/ Lipids
/ Male
/ Placebos
/ Plasma
